Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors

Chemico-Biological Interactions

Volumn 147, Issue 3, 2004, Pages 331-340

  Monostory, Katalin ^a   Hazai, Eszter ^a   Vereczkey, László ^a  

^a CHEMICAL RESEARCH CENTER   (Hungary)

Author keywords

CYP2E1; Cytochrome P450 inhibition; p Nitrophenol hydroxylase

Indexed keywords

4 NITROPHENOL; ANTIFUNGAL AGENT; BIFONAZOLE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 2E1 INHIBITOR; CYTOCHROME P450 3A4; DESIPRAMINE; DICLOFENAC; ECONAZOLE; ENZYME INHIBITOR; FLUPHENAZINE; KETOCONAZOLE; MICONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; THIORIDAZINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; IC 50; LIVER MICROSOME; MALE;

ADULT; ANTIFUNGAL AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2E1; DICLOFENAC; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; MALE; MICROSOMES, LIVER; MIDDLE AGED; NITROPHENOLS; SUBSTRATE SPECIFICITY;

EID: 2342504526     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2004.03.003     Document Type: Article

References (29)

1. D.F.V. Lewis, Substrate selectivity and metabolism, in: D.F.V. Lewis (Ed.), Guide to Cytochromes P450: Structure and Function, Taylor & Francis, London, 2001, pp. 76-117.
2. Smith G., Stubbins M.J., Harries L.W., Wolff C.R. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 28:1998;1129-1165
3. Koop D.R. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J. 6:1992;724-730
4. Chen W., Koenigs L.L., Thompson S.J., Raimund M.P., Rettie A.E., Trager W.F., Nelson S.D. Oxidation of acetaminophen to its toxic quinone metabolite and nontoxic catechol metabolites by baculovirus-expressed and human purified cytochromes P4502E1 and P4502A6. Chem. Res. Toxicol. 11:1998;295-301
5. Bessem J.G.M., Vermeulen N.P.E. Paracetamol (acetaminophen)-induced toxicity: analogues and protective approaches. Crit. Rev. Toxicol. 31:2001;55-138
6. Shu L., Hollenberg P.L. Role of cytochrome P450 in DNA damage induced by N-nitrosodialkylamines in cultured rat hepatocytes. Carcinogenesis. 17:1996;569-576
7. T.K.H. Chang, D.J. Waxman, Catalytic assays for human cytochrome P450, in: I.R. Phillips, E.A. Shephard (Eds.), Cytochrome P450 Protocols, Humana Press, Totowa, NJ, 1998, pp. 95-102.
8. Peter R., Böcker R., Beaune P.H., Iwasaki M., Guengerich F.P., Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3:1990;566-573
9. Yang C.S., Yoo J.-S.H., Ishizaki H., Hong J. Cytochrome P450IIE1 in nitrosamine metabolism and mechanism of regulation. Drug Metab. Rev. 22:1990;147-159
10. Reinke L.A., Moyer M.J. p-Nitrophenol hydroxylation: a microsomal oxidation which is highly inducible by ethanol. Drug Metab. Dispos. 13:1985;548-552
11. Koop D.R., Laethem C.L., Tierney D.J. The utility of p-nitrophenol hydroxylation in P450IIE1 analysis. Drug Metab. Rev. 20:1989;541-551
12. Tassaneeyakul W., Birkett D.J., Miners J.O. Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 28:1998;293-301
13. Hazai E., Vereczkey L., Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem. Biophys. Res. Commun. 291:2002;1089-1094
14. van der Hoeven T.A., Coon M.J. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249:1974;6302-6310
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193:1951;265-275
16. Raunio H., Syngelma T., Pasanen M., Juvonen R., Honkakoski P., Kairaluoma M.A., Sotaniemi E., Lang M.A., Pelkonen O. Immunochemical and catalytical studies on hepatic coumarin-7-hydroxylase in man, rat and mouse. Biochem. Pharmacol. 37:1988;3889-3895
17. Miners J.O., Birkett D.J. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol. 272:1996;139-145
18. Srivastava P.K., Yun C.-H., Beaune P.H., Ged C., Guengerich F.P. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40:1991;69-79
19. Guengerich F.P., Martin M.V., Beaune P.H., Kremers P., Wolff T., Waxman D.J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261:1986;5051-5060
20. Zerilli A., Ratanasavanh D., Lucas D., Goasduff T., Dreano Y., Menard C., Picart D., Berthou F. Both cytochromes P4502E1 and 3A are involved in the O-hydroxylation of p-nitrophenol, a catalytic activity known to be specific for P4502E1. Chem. Res. Toxicol. 10:1997;1205-1212
21. P.R. Ortiz de Montellano, N.O. Reich, Inhibition of cytochrome P-450 enzymes, in: P.R. Ortiz de Montellano (Ed.), Cytochrome P-450: Structure, Mechanism, and Biochemistry, Plenum Press, London, 1986, pp. 273-314.
22. Sheets J.J., Mason J., Wise C.A., Estabrook R.W. Inhibition of rat liver microsomal cytochrome P-450 steroid hydroxylase reactions by imidazole antimycotic agents. Biochem. Pharmacol. 35:1986;487-491
23. P. Maurel, The CYP3 family, in: C. Ioannides (Ed.), Cytochromes P450: Metabolic and Toxicological Aspects, CRC Press, Boca Raton, FL, 1996, pp. 241-270.
24. Sai Y., Dai R., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin H.V., Shou M. Assessment of specifity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica. 30:2000;327-343
25. Zhang W., Ramamoorthy Y., Kilicarslan T., Nolte H., Tyndale R.F., Sellers E.M. Inhibition of cytochromes P450 by antifungal imidazole derivates. Drug Metab. Dispos. 30:2002;314-318
26. Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., Maurel P. Effects of imidazole derivates on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6:1992;752-758
27. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Therap. 277:1996;321-332
28. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Effects of antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokin. 38:2000;111-180
29. Mancy A., Antignac M., Minoletti C., Dijols S., Mouries V., Duong N.T., Battioni P., Dansette P.M., Mansuy D. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochem. 38:1999;14264-14270